INTRODUCTION
============

Urinary tract infections (UTIs) are the second most common type of infection found in any organ system, and the most common type of nosocomial infection ([@B4]). These UTIs are responsible for over eight million doctors visits per year in the U.S. ([@B27]), and result in medical costs of over six billion dollars worldwide per year ([@B2]; [@B17]). Most UTIs (80--90%) are the result of infections with *Escherichia coli* ([@B15]). Non-pathogenic strains of *E. coli* are an important part of the normal flora in the human intestinal tract.

The strains of *E. coli* that infect the urinary tract are categorized as uropathogenic *E. coli* (UPEC; [@B14]). The UPEC are able to produce special surface proteins (adhesins) that allow them to attach to and invade the epithelial cells that line the urinary bladder ([@B1]; [@B32]; [@B16]; [@B23]). If the infection is not eradicated while it is in the bladder (uncomplicated UTI), some strains of UPEC may then travel up the ureters to the kidneys and cause even more severe infections (complicated UTIs), which can lead to renal damage and possibly renal failure ([@B14]; [@B30]). There are 14 serogroups of UPEC that are most commonly found in UTIs, and 75% of UTIs have been shown to be caused by serogroups 04, 06, 014, 022, 075, and 083 ([@B34]; [@B20]). The most common serogroups involved in causing UTIs worldwide are 02, 04, 06, and 075 ([@B9]). In the U.S., 49% of UTIs in women have been found to be caused by serogroups 06, 04, and 075, in descending frequency of occurrence ([@B38]).

The antimicrobial agents that have traditionally been used to treat UTIs (β-lactams, fluoroquinolones, trimethoprim--sulfamethoxazole, nitrofurantoin, etc.) are becoming less effective ([@B42]; [@B40]). In recent years, the number of antimicrobial resistant strains of *E. coli* isolated from UTIs has been increasing, including resistance to antimicrobial agents normally used to treat UTIs ([@B31]; [@B13]; [@B26]; [@B18]; [@B45]). Even though scientists are constantly working to develop new and improved antimicrobials, almost as soon as a new drug is released, the bacteria show resistance to it. These isolates are also showing resistance to drug combinations such as amoxicillin/clavulanic acid, piperacillin/tazobactam, and trimethoprim/sulfamethoxazole ([@B7]; [@B11]; [@B12]; [@B25]; [@B29]).

Green tea is derived from non-fermented leaves of the *Camellia sinensis* plant. Oolong and black tea are made from fermented leaves of the same plant. Green tea has been a favored drink, traditionally, in Asian countries. Because of studies that have shown the potential health benefits of green tea, it is now gaining worldwide popularity as a drink that is important in preventative medicine. Studies using green tea have shown it to have potential benefits, most notably in: cardiovascular disease, cancer, diabetes, obesity, oral health, bone health, and cognitive function ([@B24]; [@B3]; [@B5]; [@B22]). In addition, green tea has been shown to have antimicrobial effects ([@B43]; [@B37]; [@B8]; [@B33]).

The components in green tea that are responsible for these various effects are polyphenols (also known as catechins). The main catechins in green tea are (-)-epicatechin (EC), (-)-epicatechin-3-gallate (ECG), (-)-epigallocatechin (EGC), and (-)-epigallocatechin-3-gallate (EGCG), which have been shown to make up approximately 30--40% of the water-soluble solids in brewed green tea ([@B41]). Three of these catechins, ECG, EGC, and EGCG have been show to have antimicrobial effects against a wide variety of microorganisms ([@B43]; [@B35], [@B36]; [@B37]; [@B8]; [@B33]). The two found in the highest amounts in green tea are EGC and EGCG. Both of these are excreted in bile, but EGC is also excreted in the urine, suggesting the possibility for green tea having antimicrobial activity in UTIs ([@B44]; [@B19]; [@B3]; [@B21]). Most of the studies on how these compounds accomplish the antibacterial activity have focused on EGCG. Because EGCG is not excreted in the urine ([@B44]), it is not the compound of interest for this study. One study has found that EGC is able to bind to the ATP binding site of the bacterial gyrase B subunit, thus inhibiting gyrase activity ([@B10]). The aim of the current study was to investigate the susceptibility of UPEC strains, representing a wide variety of antimicrobial susceptibility patterns, to green tea.

MATERIALS AND METHODS {#s1}
=====================

BACTERIA STRAINS
----------------

The bacterial strains used in this study were part of a research collection of *E. coli* isolated from UTI cultures during the years of 2007--2008. There were 80 isolates selected from this collection that represented a wide spectrum of antimicrobial susceptibility patterns; in addition, two control strains that were susceptible to all the clinically tested (prior to this study) antimicrobials were selected. **Table [1](#T1){ref-type="table"}** shows the antimicrobial agents tested and frequency of the strains that were resistance to each drug.

###### 

Frequency of the antimicrobial resistance of *E. coli* strains used in this study.

  Antimicrobial                   Resistant, *n* (%)
  ------------------------------- --------------------
  Ampicillin                      63 (78)
  Piperacillin                    57 (71)
  Ampicillin/sulbactam            53 (66)
  Tetracycline                    35 (44)
  Ciprofloxacin                   33 (41)
  Trimethoprim/sulfamethoxazole   29 (36)
  Cefazolin                       12 (15)
  Gentamicin                      12 (15)
  Tobramycin                      10 (13)
  Cefuroxime                      9 (11)
  Amoxicillin/clavulanic acid     7 (9)
  Aztreonam                       5 (6)
  Ceftriaxone                     5 (6)
  Nitrofurantoin                  5 (6)
  Cefepime                        4 (5)
  Norfloxacin                     3 (4)
  Piperacillin/tazobactam         2 (3)

GREEN TEA EXTRACT
-----------------

A standardized green tea (*C. sinensis*) extract (standardized to 7.0% polyphenols) was obtained from Swanson Vitamins^®^. The plant extract was prepared in water.

MEDIA
-----

The media used in these experiments was Luria-Bertani (LB) broth (Teknova brand), and dehydrated Müller-Hinton agar (MHA; BD brand).

MINIMUM INHIBITORY CONCENTRATION DETERMINATION
----------------------------------------------

The minimum inhibitory concentration (MIC) of the green tea extract was determined by agar dilution method. MHA plates that contained various concentrations of green tea extract (0, 2.5, 3.0, 3.5, and 4.0 mg/ml) were prepared. Suspensions of 0.5 McFarland standard dilutions (equal to 1.5 × 10^8^ cells/ml) were prepared from bacterial cultures grown overnight in LB broth. A 10^-4^ dilution of these suspensions was prepared, and 100 μl of dilution per plate was inoculated using a spread plate technique (plated concentration equals 1.5 × 10^3^ cells). Inoculated plates were incubated at 37° C for 48 h, and on the basis of colony counts, the MIC was determined as the lowest concentration of green tea extract to show an inhibitory effect on growth of the bacteria (no colonies detected). Each strain was tested three times.

RESULTS
=======

MIC DETERMINATION
-----------------

The MICs and susceptibility results are as follows: 99% were susceptible to the green tea extract at a concentration of ≤4.0 mg/ml (one strain was not susceptible at even 4.0 mg/ml); 94% were susceptible at ≤3.5 mg/ml; 76% were susceptible at ≤3.0 mg/ml; 40%, were susceptible at ≤2.5 mg/ml; The control strains varied; one being susceptible at ≤2.5 mg/ml and the other susceptible at ≤3.5 mg/ml. **Table [2](#T2){ref-type="table"}** shows the MIC results for the 79 strains that were susceptible at ≤4.0 mg/ml.

###### 

Minimum inhibitory concentrations for total green tea extract (GTE) and the EGC component.

  Component           Number of isolates tested (% out of 79)                 
  ------------------- ----------------------------------------- ------ ------ ------
  Total GTE (mg/ml)   ≤2.5                                      ≤3.0   ≤3.5   ≤4.0
  EGCμg/ml)           ≤450                                      ≤540   ≤630   ≤720

DISCUSSION
==========

The green tea extract was shown to have an inhibitory effect on the growth of *E. coli* strains isolated from UTIs. The MIC results can be adjusted to reflect the EGC content, using a value of 18% EGC as the content in total green tea polyphenols ([@B39]). That makes the adjusted results as follows: 40% of strains tested were susceptible at a concentration of EGC at ≤0.45 mg/ml (450 μg/ml); 36% susceptible at ≤0.54 mg/ml (540 μg/ml); 18% susceptible at ≤0.63 mg/ml (630 μg/ml); and 5% susceptible at ≤0.72 mg/ml (720 μg/ml). Since all of the strains tested (99%) were susceptible at a concentration of ≤0.72 mg/ml, this suggests that EGC might be a good inhibitor of bacterial growth. **Table [2](#T2){ref-type="table"}** shows the MIC data for total green tea extract and for the EGC component.

The data was collected by *in vitro* experiments, but the effect can be described using information that is known about the metabolism of EGC from green tea. The amount of green tea polyphenols that would be present in the urine, including the amount of EGC, will vary according to the origin of the tea. It has been found, for instance, that Japanese tea (an average of 15 teas) contains approximately 20 mg of EGC per gram of dry tea ([@B39]). An average cup of Japanese green tea is made with one tablespoon of dry tea (instructions from package of tea) which is equivalent to approximately 7.5 g of dry tea (a package of 60 g of dry tea makes eight cups). That equates to approximately 150 mg of EGC per cup of Japanese green tea.

Urinary excretion after a single ingested dose of EGC has been shown to peak at 8 h after ingestion, with levels in the urine reaching to 3.0--5.0 mg ([@B44]). The amount of EGC excreted after ingestion of one cup of tea (as described above) should equal approximately 3.5 mg. Since the projected MICs for EGC are well below 3.5 mg, this suggests that even one cup of green tea could have an effect on a urinary tract pathogen, and drinking multiple cups over the course of a day could possibly provide a prolonged effect. Additional studies testing the *in vivo* effect of drinking green tea on UTIs could be useful for determining if the effects observed in this study have medical significance.

Studies have shown that concentrations of 500 μg of tea polyphenols can inhibit the growth of *E. coli*, and that concentrations of ≥5000 μg are considered bactericidal. This effect is believed to be due to the fact that tea polyphenols down regulate the production of proteins such as EF-2 (elongation factor for protein translation); proteins involved in phospholipid, carbon, and energy metabolism; and production of proteins involved in amino acid biosynthesis ([@B6]).

There was no correlation between MIC values in this study and the antimicrobial resistance of the isolates. Each level of MIC contained a variety of antimicrobial resistance patterns.

Another set of studies that would be interesting and potentially useful would be to test EGC and several of the standard antimicrobial agents used to treat UTIs to determine if there might be synergism between EGC and any of the antimicrobial agents. Studies have been done that show the ability of green tea to act synergistically with gentamicin and amikacin against *E. coli* ([@B28]).

CONCLUSION
==========

The results of this study have shown that green tea can have an antimicrobial effect on *E. coli* bacteria that cause UTIs. This is the first time that green tea has been reported to have this kind of effect. The data also adds to the current information on the potential health benefits of green tea. It is our hope that these findings will encourage further studies on the antimicrobial potential of green tea and other plant components.
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